Centene announced that it has successfully completed the previously announced divestiture of Magellan Rx to Prime Therapeutics LLC. Centene acquired Magellan Rx in January 2022 as part of its acquisition of Magellan Health.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CNC:
- CENTENE COMPLETES DIVESTITURE OF MAGELLAN RX
- Managed care company returns will be tough to keep replicating, WSJ says
- CENTENE SIGNS DEFINITIVE AGREEMENT TO DIVEST MAGELLAN SPECIALTY HEALTH
- EVOLENT HEALTH ANNOUNCES ACQUISITION OF SPECIALTY ASSET NIA AND STRATEGIC PARTNERSHIP WITH CENTENE
- CENTENE COMPLETES DIVESTITURE OF ITS SPANISH AND CENTRAL EUROPEAN BUSINESSES